SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-035948
Filing Date
2022-12-20
Accepted
2022-12-20 08:30:31
Documents
15
Period of Report
2022-12-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 54407
2 ex10-1.htm EX-10.1 498541
3 ex99-1.htm EX-99.1 36609
4 ex99-1_001.jpg GRAPHIC 2404
  Complete submission text file 0001493152-22-035948.txt   861138

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE prph-20221215.xsd EX-101.SCH 3239
6 XBRL LABEL FILE prph-20221215_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE prph-20221215_pre.xml EX-101.PRE 22367
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3607
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 221472881
SIC: 2834 Pharmaceutical Preparations